GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Float Percentage Of Total Shares Outstanding

Fennec Pharmaceuticals (STU:RV41) Float Percentage Of Total Shares Outstanding : 68.44% (As of May. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Fennec Pharmaceuticals's float shares is 18.70 Mil. Fennec Pharmaceuticals's total shares outstanding is 27.32 Mil. Fennec Pharmaceuticals's float percentage of total shares outstanding is 68.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Fennec Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Fennec Pharmaceuticals's Institutional Ownership is 13.54%.

Fennec Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Fennec Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=18.70/27.32
=68.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals (STU:RV41) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TSX:MDNA TSXV:NGEN NEOE:CYBN TSX:EPRX XCNQ:ACOG TSX:ONC TSXV:ARCH XCNQ:METX TSX:SVA TSX:TH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
FENC:USA FRX:Canada
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Website
https://www.fennecpharma.com
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines